Allworth Financial LP Cuts Stake in Pfizer Inc. $PFE

Key Points

• Allworth Financial cut its Pfizer stake by 25.7% in the second quarter, selling 124,640 shares and retaining 360,280 shares valued at approximately $8.68 million. Institutional investors collectively own 68.36% of Pfizer.
• Pfizer’s latest quarterly results exceeded expectations, with adjusted EPS of $0.77 versus $0.68 expected and revenue of $15.03 billion versus $14.40 billion forecast. The company maintained 2026 EPS guidance of $2.80–$3.00.
• Pfizer offers a 6.2% dividend yield, but its 226% payout ratio and limited projected dividend growth remain concerns. Analysts maintain a consensus “Hold” rating with an average price target of $28.28.

Allworth Financial LP reduced its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 25.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 360,280 shares of the biopharmaceutical company's stock after selling 124,640 shares during the period. Allworth Financial LP's holdings in Pfizer were worth $8,676,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Evolution Wealth Management Inc. raised its holdings in shares of Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 566 shares during the period. Godfrey Financial Associates Inc. acquired a new position in Pfizer in the 4th quarter valued at about $26,000. Keb Asset Management LLC acquired a new position in Pfizer in the 2nd quarter valued at about $26,000. HFM Investment Advisors LLC increased its holdings in shares of Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 427 shares during the last quarter. Finally, Field & Main Bank purchased a new stake in shares of Pfizer during the 2nd quarter valued at approximately $27,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s recent quarterly results exceeded expectations, with adjusted earnings per share of $0.77 versus a $0.68 consensus estimate and revenue of $15.03 billion, above the $14.40 billion forecast. The earnings beat helped revive the shares during August and supports confidence in the company’s ability to execute despite post-COVID revenue challenges. Why Pfizer Stock Was so Healthy in August
• Positive Sentiment: Pfizer’s roughly 6% dividend yield remains a major attraction for income-focused investors. Some analysts also see upside from a pipeline that is beginning to gain investor attention, with one commentary assigning a 12-month price target of $32.72 based on dividend support and potential pipeline progress. Forget the Dividend: This Could Be the Real Reason to Buy Pfizer Stock Now
• Neutral Sentiment: Chief Executive Officer Albert Bourla is scheduled to speak at the Morgan Stanley Global Healthcare Conference on September 14. Investors may look for updates on the pipeline, capital allocation and the company’s growth strategy. Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
• Negative Sentiment: Pfizer’s high yield is not viewed as the strongest dividend-growth opportunity. Comparisons with AbbVie argue that Pfizer offers income today but may have less attractive long-term dividend growth, potentially limiting demand from total-return investors. Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now
• Negative Sentiment: Novartis India’s $132 million acquisition of Pfizer brands indicates continued portfolio reshaping, but the divestiture also removes established products and revenue from Pfizer’s business. Meanwhile, Lilly’s expanding neuroscience pipeline highlights intensifying competition for future growth in innovative medicines. Novartis India Acquires Pfizer Brands

Pfizer Price Performance

Pfizer stock opened at $27.78 on Wednesday. The company's 50 day moving average is $26.13 and its two-hundred day moving average is $26.35. The firm has a market cap of $158.34 billion, a PE ratio of 36.55, a price-to-earnings-growth ratio of 1.91 and a beta of 0.34. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 52-week low of $23.58 and a 52-week high of $29.21.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion during the quarter, compared to analysts' expectations of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.Pfizer's revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts expect that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th were given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.2%. The ex-dividend date was Friday, July 24th. Pfizer's payout ratio is currently 226.32%.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. HSBC cut Pfizer from a "buy" rating to a "hold" rating and cut their target price for the stock from $32.00 to $28.00 in a research note on Monday, July 6th. Royal Bank Of Canada upgraded shares of Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price objective on the stock in a report on Tuesday, June 9th. Weiss Ratings raised shares of Pfizer from a "hold (c-)" rating to a "hold (c)" rating in a research note on Monday, August 31st. Bank of America reduced their price target on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a research note on Friday, July 10th. Finally, UBS Group reaffirmed a "neutral" rating and set a $27.00 price objective on shares of Pfizer in a research report on Wednesday, May 27th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $28.28.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer's products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.